| Georges Almacari, MD | |
|
110 Liberty St, Brockton, MA 02301-5521 | |
| (508) 565-3055 | |
| (508) 894-0757 |
| Full Name | Georges Almacari |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 27 Years |
| Location | 110 Liberty St, Brockton, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326152216 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 226629 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna Care Network | Worcester, MA | Home health agency |
| Brockton Vna | Brockton, MA | Home health agency |
| Visiting Nurse Association Of Boston | Dorchester, MA | Home health agency |
| Bayada Home Health Care , Inc | Hyannis, MA | Home health agency |
| Natick Walpole Visiting Nurse Association | Walpole, MA | Home health agency |
| New England Baptist Hospital | Boston, MA | Hospital |
| Signature Healthcare Brockton Hospital | Brockton, MA | Hospital |
| Tufts Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atrius Health Inc | 4789588641 | 1116 |
| Signature Healthcare Medical Group Inc | 7719876267 | 167 |
News Archive
A Yale-led group of doctors has developed a new mathematical model that can predict the risk of acute kidney injury (AKI) in patients undergoing a common heart procedure.
Women who stopped taking the postmenopausal hormone combination of estrogen plus progestin experienced a marked decline in breast cancer risk which was unrelated to mammography utilization change, according to a study from the Women's Health Initiative led by a Los Angeles Biomedical Research Institute (LA BioMed) investigator that was published today in The New England Journal of Medicine.
Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has concluded its tender offer and acquired a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities creates a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field.
Eli Lilly and Company announced today it will discontinue development of tabalumab - being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) - due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns.
One consequence of the COVID-19 pandemic is that more families are putting off their children's preventive care visits, causing pediatric providers to worry about missed vaccines.
› Verified 6 days ago
| Entity Name | Atrius Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871639914 PECOS PAC ID: 4789588641 Enrollment ID: O20031121000582 |
News Archive
A Yale-led group of doctors has developed a new mathematical model that can predict the risk of acute kidney injury (AKI) in patients undergoing a common heart procedure.
Women who stopped taking the postmenopausal hormone combination of estrogen plus progestin experienced a marked decline in breast cancer risk which was unrelated to mammography utilization change, according to a study from the Women's Health Initiative led by a Los Angeles Biomedical Research Institute (LA BioMed) investigator that was published today in The New England Journal of Medicine.
Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has concluded its tender offer and acquired a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities creates a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field.
Eli Lilly and Company announced today it will discontinue development of tabalumab - being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) - due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns.
One consequence of the COVID-19 pandemic is that more families are putting off their children's preventive care visits, causing pediatric providers to worry about missed vaccines.
› Verified 6 days ago
| Entity Name | Signature Healthcare Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508804949 PECOS PAC ID: 7719876267 Enrollment ID: O20040312000372 |
News Archive
A Yale-led group of doctors has developed a new mathematical model that can predict the risk of acute kidney injury (AKI) in patients undergoing a common heart procedure.
Women who stopped taking the postmenopausal hormone combination of estrogen plus progestin experienced a marked decline in breast cancer risk which was unrelated to mammography utilization change, according to a study from the Women's Health Initiative led by a Los Angeles Biomedical Research Institute (LA BioMed) investigator that was published today in The New England Journal of Medicine.
Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has concluded its tender offer and acquired a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities creates a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field.
Eli Lilly and Company announced today it will discontinue development of tabalumab - being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) - due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns.
One consequence of the COVID-19 pandemic is that more families are putting off their children's preventive care visits, causing pediatric providers to worry about missed vaccines.
› Verified 6 days ago
| Entity Name | Physicians Of Falmouth Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821363698 PECOS PAC ID: 6800051970 Enrollment ID: O20120625000127 |
News Archive
A Yale-led group of doctors has developed a new mathematical model that can predict the risk of acute kidney injury (AKI) in patients undergoing a common heart procedure.
Women who stopped taking the postmenopausal hormone combination of estrogen plus progestin experienced a marked decline in breast cancer risk which was unrelated to mammography utilization change, according to a study from the Women's Health Initiative led by a Los Angeles Biomedical Research Institute (LA BioMed) investigator that was published today in The New England Journal of Medicine.
Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has concluded its tender offer and acquired a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities creates a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field.
Eli Lilly and Company announced today it will discontinue development of tabalumab - being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) - due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns.
One consequence of the COVID-19 pandemic is that more families are putting off their children's preventive care visits, causing pediatric providers to worry about missed vaccines.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Georges Almacari, MD 110 Liberty St, Brockton, MA 02301-5521 Ph: (508) 565-3055 | Georges Almacari, MD 110 Liberty St, Brockton, MA 02301-5521 Ph: (508) 565-3055 |
News Archive
A Yale-led group of doctors has developed a new mathematical model that can predict the risk of acute kidney injury (AKI) in patients undergoing a common heart procedure.
Women who stopped taking the postmenopausal hormone combination of estrogen plus progestin experienced a marked decline in breast cancer risk which was unrelated to mammography utilization change, according to a study from the Women's Health Initiative led by a Los Angeles Biomedical Research Institute (LA BioMed) investigator that was published today in The New England Journal of Medicine.
Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has concluded its tender offer and acquired a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities creates a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field.
Eli Lilly and Company announced today it will discontinue development of tabalumab - being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) - due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns.
One consequence of the COVID-19 pandemic is that more families are putting off their children's preventive care visits, causing pediatric providers to worry about missed vaccines.
› Verified 6 days ago
Scott Joseph Mandel, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Liberty St, Brockton, MA 02301 Phone: 508-894-0400 Fax: 508-894-0757 | |
Dr. Francis Mccormick, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Liberty St, Suite 1a, Brockton, MA 02301 Phone: 508-565-3055 Fax: 508-894-0757 | |
Arthur P Carriere, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 110 Liberty Street, Brockton, MA 02301 Phone: 508-894-0400 Fax: 508-565-0157 | |
George C Brown, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 110 Liberty St, Brockton, MA 02301 Phone: 508-894-0400 Fax: 508-894-0757 | |
Larry Victor Lee, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Liberty St, Brockton, MA 02301 Phone: 508-565-3055 Fax: 508-894-0757 | |
Marshal S Armitage, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Liberty St, Brockton, MA 02301 Phone: 508-894-0400 Fax: 508-894-0757 |